The journal of breast health最新文献_第3页

Three Cases of Breast Metastases from Lung Cancer and Systematic Review of the Literature. 肺癌乳腺转移3例及文献系统复习。

The journal of breast health Pub Date : 2020-05-22 DOI: 10.5152/ejbh.2020.5703

N. Güldoğan, G. E. İçten, F. Tokat, B. Tutar, H. Kara, T. Korkmaz, B. Oyan Uluç, G. Demir

引用次数: 2

Desmoid Type Fibromatosis of the Breast Masquerading as Breast Carcinoma: Value of Dynamic Magnetic Resonance Imaging and Its Correlation. 伪装成乳腺癌的乳腺硬纤维瘤病:动态磁共振成像的价值及其相关性。

The journal of breast health Pub Date : 2020-05-20 DOI: 10.5152/ejbh.2020.5482

Wei Lin Ng, Sze Yong Teoh, M. See, K. Rahmat, P. Jayalakshmi, M. T. Ramli, M. Teh, A. Vijayananthan

引用次数: 2

15th. National Breast Diseases Congress Abstract Book 第十五国家乳腺疾病大会摘要书

The journal of breast health Pub Date : 2020-01-10 DOI: 10.5152/ejbh.2019.929092

引用次数: 0

Erratum. 勘误表。

The journal of breast health Pub Date : 2020-01-01 DOI: 10.5152/ejbh.2019.231219

引用次数: 0

Erratum. 勘误表。

The journal of breast health Pub Date : 2020-01-01 DOI: 10.5152/ejbh.2019.2312019

引用次数: 0

Diffusion-Weighted Imaging of Breast Cancer: Correlation of the Apparent Diffusion Coefficient Value with Pathologic Prognostic Factors. 癌症扩散加权成像：表观扩散系数和病理预后因素的相关性。

The journal of breast health Pub Date : 2019-10-01 DOI: 10.5152/ejbh.2019.4860

Şehnaz Tezcan, N. Uslu, F. Öztürk, E. Akçay, T. Tezcaner

{"title":"Diffusion-Weighted Imaging of Breast Cancer: Correlation of the Apparent Diffusion Coefficient Value with Pathologic Prognostic Factors.","authors":"Şehnaz Tezcan, N. Uslu, F. Öztürk, E. Akçay, T. Tezcaner","doi":"10.5152/ejbh.2019.4860","DOIUrl":"https://doi.org/10.5152/ejbh.2019.4860","url":null,"abstract":"Objective\u0000The aim was to evaluate relationship between apparent diffusion coefficient (ADC) values with pathologic prognostic factors in breast carcinoma (BC).\u0000\u0000\u0000Materials and Methods\u000083 patients were enrolled in this study. Prognostic factors included age, tumor size, expression of estrogen receptor (ER) and progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), nuclear grade (NG), lymph node involvement and histologic type. The relationship between ADC and prognostic factors was determined using Independent sample t-test, ANOVA, Pearson correlation and relative operating characteristics (ROC) analysis.\u0000\u0000\u0000Results\u0000There was no significant difference between ADC and prognostic factors, including age, tumor size, ER, HER2 and histologic type. The PR-positive tumors (p=0.03) and axillary lymph node involvement (p=0.000) showed a significant association with lower ADC values. The ADC values were significantly lower in high-grade tumors than low-grade tumors (p=0.000). ROC analysis showed an optimal ADC threshold of 0.66 (×10-3 mm2/s) for differentiating low-grade tumors from high-grade tumors (sensitivity, 85.5%; specificity, 81%; area under curve, 0.90).\u0000\u0000\u0000Conclusion\u0000The lower ADC values of BC were significantly associated with positive expression of PR, LN positivity and high-grade tumor. Especially, ADC values were valuable in predicting NG subgroups.","PeriodicalId":91975,"journal":{"name":"The journal of breast health","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43015577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 6

Correlation between the Expression of PD-L1 and Clinicopathological Parameters in Triple Negative Breast Cancer Patients. 三阴性乳腺癌患者PD-L1表达与临床病理参数的关系

The journal of breast health Pub Date : 2019-10-01 DOI: 10.5152/ejbh.2019.4912

Rabia Doğukan, R. Uçak, F. M. Doğukan, C. Tanık, B. Citgez, F. Kabukçuoğlu

{"title":"Correlation between the Expression of PD-L1 and Clinicopathological Parameters in Triple Negative Breast Cancer Patients.","authors":"Rabia Doğukan, R. Uçak, F. M. Doğukan, C. Tanık, B. Citgez, F. Kabukçuoğlu","doi":"10.5152/ejbh.2019.4912","DOIUrl":"https://doi.org/10.5152/ejbh.2019.4912","url":null,"abstract":"Objective\u0000Triple-negative breast cancer (TNBC) is a heterogenous group of tumors with no estrogen receptor (ER), progesterone receptor (PR) and Cerb-B2/HER2 expression. Programmed death ligand-1 (PD-L1) is a transmembrane protein located on both non-tumor and tumor cells and it has been shown to be associated with the escape of tumor cells from the immune system. PD-L1-targeted therapy alone or in combination is now an alternative strategy in several aggressive tumor types. In this respect, TNBC is a potential candidate having limited treatment options and poor outcome.\u0000\u0000\u0000Material and Methods\u0000Sixty-one breast cancers with no expression of ER, PR and Cerb-B2/HER2 were chosen to study PD-L1 immunohistochemistry. PD-L1 staining and its correlation with main clinicopathological parameters were evaluated.\u0000\u0000\u0000Results\u0000The percentage of PD-L1 positivity was 37.7% and 47.5% in tumor and tumor microenvironment, respectively. The positivity rate was higher in breast carcinomas with medullary features (83.3%) and metaplastic carcinoma (66.6%) subgroups. PD-L1 expression of tumors was positively correlated with their Ki-67 score and PD-L1 positivity of the tumor microenvironment. No significant relationship was found between the other variables.\u0000\u0000\u0000Conclusion\u0000PD-L1 expression rate was remarkable both in the tumor and the tumor microenvironment of TNBCs. Larger cohorts of TNBC are required to further describe their PD-L1 expression characteristics and help standardize PD-L1 immunohistochemistry assays in these tumors.","PeriodicalId":91975,"journal":{"name":"The journal of breast health","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45647471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 20

Comparison of Clinical Features and Treatment Results of Mix Mucinous Carcinomas and Other Atypical Carcinomas of the Breast. 乳腺混合粘液癌和其他不典型癌的临床特点及治疗效果比较。

The journal of breast health Pub Date : 2019-10-01 DOI: 10.5152/ejbh.2019.5032

Mustafa Gök, Uğur Topal, Bahadır Öz, Hülya Akgün, Alper Celal Akcan, Erdoğan Mütevelli Sözüer

{"title":"Comparison of Clinical Features and Treatment Results of Mix Mucinous Carcinomas and Other Atypical Carcinomas of the Breast.","authors":"Mustafa Gök, Uğur Topal, Bahadır Öz, Hülya Akgün, Alper Celal Akcan, Erdoğan Mütevelli Sözüer","doi":"10.5152/ejbh.2019.5032","DOIUrl":"10.5152/ejbh.2019.5032","url":null,"abstract":"Objective: There are multiple subtypes of breast cancer with different biological and pathological features and accordingly exhibit different clinical behaviors. The aim of this study was to compare the treatment modalities, clinical features and prognostic characteristics of Mix Mucinous Carcinomas (MMBC) and other rare tumors of the breast.Materials and method: A total of 2152 patients who were operated on for breast cancer in our clinic between 2010-2019, with pathological diagnoses of tubular, pure mucinous, mix mucinous or papillary carcinoma were enrolled in the study. Patients were divided into two groups as mix mucinous patients (Group1) and other rare tumors (Group2). The demographic, clinical and prognostic characteristics and treatment approaches were compared between Groups, and additionally between the subtypes of Group 2.Results: 42 patients participated in our study. Group 1 consisted of 7 patients, and Group2 consisted of 35 patients. The subtypes in Group2 were papillary (n=21), pure mucinous (n=10) and tubular (n=4). Progesterone Receptor Positivity was found to be significantly higher in Group 2 patients than in Group1 patients (p=0.005, p<0.05). Multicentricity rates in the tumors of the patients in Group1 were found to be statistically significantly higher than the patients in Group 2 (p=0.024, p<0.05). In subtype analysis in Group2, there were no statistically significant differences parameters in the subgroups (p>0.05). Mean survival was 19.5+5.6 (8.5-30.5) months in Group 1 and 46.3+5.2 (36.1-56.6) months, in Group2 when evaluated separately (p:0.002).Conclusion: The prognosis of pure mucinosis (PMBC) and other atypical cancers of the breast compared to the (MMBC) is quite good. Rare pathological types of breast cancer can have favorable outcomes when treated with necessary oncological principles.","PeriodicalId":91975,"journal":{"name":"The journal of breast health","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6776130/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47919224","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prognostic Importance of Ki-67 in Breast Cancer and Its Relationship with Other Prognostic Factors. Ki-67在乳腺癌预后中的重要性及其与其他预后因素的关系。

The journal of breast health Pub Date : 2019-10-01 DOI: 10.5152/ejbh.2019.4778

G. Kanyilmaz, B. Yavuz, M. Aktan, M. Karaağaç, M. Uyar, S. Fındık

{"title":"Prognostic Importance of Ki-67 in Breast Cancer and Its Relationship with Other Prognostic Factors.","authors":"G. Kanyilmaz, B. Yavuz, M. Aktan, M. Karaağaç, M. Uyar, S. Fındık","doi":"10.5152/ejbh.2019.4778","DOIUrl":"https://doi.org/10.5152/ejbh.2019.4778","url":null,"abstract":"Objective\u0000The clinical feature of breast cancer is very heterogeneous because of the variable prognostic factors impact its behaviour. The aim of study is to find the prognostic importance of Ki-67 and to analyse the correlation between Ki-67 index and the other conventional prognostic factors in breast cancer patients.\u0000\u0000\u0000Materials and Methods\u0000Between 2010 and 2017, patients with invasive ductal carcinoma who received radiotherapy after surgery were included in study. A single pathologist re-defined of all cases retrospectively. Ki-67 were established three categories based on Ki-67 levels: low (<10%), intermediate (10-25%) and high (>25%).\u0000\u0000\u0000Results\u0000A total of 258 patients were included. 46 of 258 (18%) patients were in low, 82 of 258 (32%) patients were in intermediate and 130 of 258 (50%) patients were in high Ki-67 group. There were no correlations between menopausal status, age, and Ki-67 level. Low-pT stages tended to have low Ki-67 expression (p=0.07). Low-pN stages correlated with low Ki-67 values (p=0.007). Patients with ECE (+) were prone to have higher Ki-67 values (p=0.02). The significant correlation was seen between Ki-67 and tumour grading (p=<0.0001). Patients with LVI (+) had higher Ki-67 expression (p=0.007). Luminal A tumours were correlated with low Ki-67 group (p=<0.0001). Ki-67 values had significant effect on DFS (p=0.03) but not OS (p=0.09).\u0000\u0000\u0000Conclusion\u0000This study showed that high Ki-67 expression is associated with higher pT-stage, higher pN-stage, higher grade, ER/PR negativity, HER2/neu positivity, ECE and LVI positivity. The prognostic impact of Ki-67 was only demonstrated for DFS.","PeriodicalId":91975,"journal":{"name":"The journal of breast health","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44418640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 42

Determining Breast Cancer Treatment Costs Using the Top Down Cost Approach. 使用自顶向下成本法确定乳腺癌治疗费用。

The journal of breast health Pub Date : 2019-10-01 DOI: 10.5152/ejbh.2019.4909

R. Tekin, Meltem Saygılı

{"title":"Determining Breast Cancer Treatment Costs Using the Top Down Cost Approach.","authors":"R. Tekin, Meltem Saygılı","doi":"10.5152/ejbh.2019.4909","DOIUrl":"https://doi.org/10.5152/ejbh.2019.4909","url":null,"abstract":"Objective\u0000Breast cancer is the most common type of cancer among women in Turkey, with approximately 15.000 breast cancer diagnoses each year. In this study, our goal was to determine annual direct medical costs of all breast cancer patients in Turkey with top down cost approach.\u0000\u0000\u0000Materials and Methods\u0000Data regarding patients who have been diagnosed with breast cancer and received health services from any hospital in Turkey in 2014 were used for the purpose of the study. Data were obtained from the MEDULA System for a total of 126.664 patient. Treatment of costs of patients were calculated based on types of patient admissions (inpatient/outpatient/intensive care) and costs of drugs and medical equipment. Indirect costs and out of pocket costs were not included.\u0000\u0000\u0000Results\u0000Total medical costs of 126,664 patients was calculated as $116.792.107,9, with an average treatment cost per patient of $922,1. Based on types of patient admission, intensive care treatment had the highest average cost with $2.916.5. In metastatic breast cancer patients, average annual treatment cost per patient is $2.326,6, which is 2.8 times higher compared to non-metastatic breast cancer patients.\u0000\u0000\u0000Conclusion\u0000In order to ensure effective resource allocation at micro and macro level, healthcare administrators have to learn costs of diseases with high incidence such as breast cancer. Results obtained from studies on disease costs calculated using the top down cost approach provide data on actual health services use and therefore are seen as important tools for healthcare administrators in terms of effective resource allocation.","PeriodicalId":91975,"journal":{"name":"The journal of breast health","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41917945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 10